{"id":"53a45a8d30bf","type":"article","url":"https://hartvaat.nl/2026/03/01/complementremmers-winnen-terrein-bij-de-behandeling-van-iga-nefropathie/","title":"Complementremmers winnen terrein bij de behandeling van IgA-nefropathie","title_en":"The expanding role of complement inhibitors in the treatment of IgA nephropathy","category":"chronische nierziekte","category_label":"Nierziekte","professions":["apotheker","internist"],"tags":["cardiorenal-behandelstrategie","complementremmers","iga-nefropathie"],"journal":"Kidney International","doi":"https://www.kidney-international.org/article/S0085-2538(25)01025-7/fulltext","source_url":"https://doi.org/https://www.kidney-international.org/article/S0085-2538(25)01025-7/fulltext","authors":["Fernando Caravaca-Fontán","Manuel Praga"],"significance":7,"published":"2026-03-01","source_date":"2026-03-01","image":"","kennis":["https://hartvaat.nl/kennis/nierziekte/raas-blokkade-bij-nierziekte/","https://hartvaat.nl/kennis/nierziekte/contrastmiddel-en-nierfunctie/"],"congress":"","summary_en":"This editorial discussed complement inhibition as an emerging therapeutic approach for IgA nephropathy, reviewing promising phase 2 results of targeted complement therapies for this common glomerular disease.","created":"2026-07-03T10:25:02Z","updated":"2026-07-03T13:24:30Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Complementactivatie is een sleutelmechanisme bij IgA-nefropathie. Dit editorial bespreekt veelbelovende fase 2-resultaten van sefaxersen, een antisense-remmer van Factor B, met verminderde proteïnurie en verbeterde hematurie. De uitdaging is nu het identificeren van de juiste patiënten voor complementgerichte therapie.","abstract_original":"Complement activation has emerged as a key driver of IgA nephropathy, catalyzing the rapid expansion of complement-targeted therapies. Barbour et al. reported promising phase 2 results of sefaxersen, an antisense inhibitor of Factor B, showing reduced proteinuria, improved hematuria, and sustained alternative-pathway inhibition. Nonetheless, as the therapeutic landscape expands, advancing precision medicine in IgA nephropathy will require defining appropriate patient profiles and predictors of therapeutic response to guide individualized treatment."}